Linked Life Data

19374998

Source:http://linkedlifedata.com/resource/pubmed/id/19374998

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-4-20
pubmed:abstractText
The generation of modified lantibiotics in whole cells has proved to be of value for the investigation of the specificity of the lantibiotic-processing enzymes and their tolerance to mutations in the primary sequence of lantibiotics. The development of methods to produce new lantibiotic variants has also enabled the investigation of the structure-activity relationships of these compounds and hence an evaluation of this hitherto underexploited class of natural products as a source of potential therapeutic drug candidates. We report the methods and strategies that have been used to engineer new lantibiotic variants and practical methods to analyze libraries of new compounds with a view toward optimizing drug properties.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1557-7988
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
458
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
559-74
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Chapter 22. Whole-cell generation of lantibiotic variants.
pubmed:affiliation
Novacta Biosystems Ltd, BioPark Hertfordshire, Welwyn Garden City, United Kingdom.
pubmed:publicationType
Journal Article